BRCA1 and ovarian carcinoma: Whereas ovarian cancer cells with BRCA1/2 mutations are sensitive to the PARP inhibitor rucaparib [14,15], multiple cell lines with wild-type BRCA1/2 show varying sensitivity to rucaparib [27].